Skip to main content

CORRECTION article

Front. Mol. Neurosci., 21 February 2022
Sec. Methods and Model Organisms
Volume 15 - 2022 | https://doi.org/10.3389/fnmol.2022.865110
This article is part of the Research Topic Blood Biomarkers of Neurodegenerative Diseases View all 26 articles

Corrigendum: Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood

This article is a correction to:

  1. Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer’s Disease in Blood

    1. Read original article
\nYuxin Guo,Yuxin Guo1,2Zhiyuan Hu,,, Zhiyuan Hu1,3,4,5*Zihua Wang Zihua Wang3*
  • 1CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China
  • 2University of Chinese Academy of Sciences, Beijing, China
  • 3Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China
  • 4School of Nanoscience and Technology, Sino-Danish College, University of Chinese Academy of Sciences, Beijing, China
  • 5School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, China

A Corrigendum on
Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood

by Guo, Y., Hu, Z., and Wang, Z. (2021). Front. Mol. Neurosci. 14:778955. doi: 10.3389/fnmol.2021.778955

In the published article, there was an error regarding the affiliations for Yuxin Guo. As well as having affiliation 1, they should also have “University of Chinese Academy of Sciences, Beijing, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Alzheimer's disease, blood biomarkers, diagnosis, peptide, peptoid

Citation: Guo Y, Hu Z and Wang Z (2022) Corrigendum: Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood. Front. Mol. Neurosci. 15:865110. doi: 10.3389/fnmol.2022.865110

Received: 29 January 2022; Accepted: 31 January 2022;
Published: 21 February 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Guo, Hu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhiyuan Hu, aHV6eSYjeDAwMDQwO25hbm9jdHIuY24=; Zihua Wang, d2FuZ3poJiN4MDAwNDA7ZmptdS5lZHUuY24=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.